Human respiratory syncytial virus (RSV) is a common respiratory virus that is now recognized as an important pathogen in adults, especially the elderly. In adults, about 1.5m episodes of RSV-ARI occur in industrialized countries. Globally, 336,000 (UR 186,000-614,000) hospital admissions and 14,000 in-hospital deaths (UR 5,000-50,000) have been estimated; however, the true burden is believed to be higher (Shi T et al., 2020; Kulkarni D et al., 2025). In the USA, 60-160,000 hospitalizations are estimated for persons >65 yrs with around 6-10,000 deaths (CDC, RSV-NET cited figures), again with wide variance in estimates. Cardiovascular, chronic lung, and diabetes are common underlying conditions in persons (>18 yrs) hospitalized with RSV infection, with in-hospital mortality at ~12% (Shi T et al., 2022). There is no specific treatment for RSV infection, and for those adults who require hospitalization, supportive therapy is still the mainstay of care.
GSK Biologicals, Pfizer and ModernaTX now have licensed RSV vaccines: Arexvy (May 2023), Abrysvo (May 2023), and mResvia (May 2024), respectively. Apart from Abrysvo, which also has a maternal indication, these vaccines are now recommended in most major markets for varying older adult elderly or at-risk age groups to prevent lower respiratory tract disease (LRTD) due to RSV. The market (including maternal use) was valued at ~$1.5bn in FY2024, albeit a decline from FY2023. Despite these strong incumbent vaccines, the RSV vaccine R&D pipeline remains very active with major competitors such as AstraZeneca (IVX-A12), Sanofi/Vicebio (SPO256, SPO291, VXB-241), ModernaTX (mRNA-1365) and Clover Pharmaceuticals (SCB-1019) hoping that coupling RSV vaccines with other major respiratory pathogens such as human metapneumovirus (hMPV) and Parainfluenza virus (PIV) could allow them to grab a share of this growing global market. Both hMPV and PIV, along with RSV, are now estimated to cause as many US hospitalizations as seasonal influenza, hence the rationale for developing further adult respiratory combination vaccines.
This MarketVIEW product is a comprehensive Executive Presentation (~375 slides, .pdf) and interactive MS-Excel forecast model(s) (~175 worksheets) which investigate the scenario-based commercial potential of RSV older adult elderly monovalent and combination vaccine profiles to 2037. 10 high-income countries are included (public/private sector), where the impact of different country-specific pricing analogues, at risk stratifications, and cohort target ranges can be visualized. The new 2025 model can explore various revaccination schedules, including: no revaccination, yearly, and 2,3, and 5-yearly schedules, and the potential country-level switching of combination products (both dual and triple formats)
This report also contains a thorough review of disease background/epidemiology/cost-effectiveness studies, along with vaccinology/R&D competitive landscape with an emphasis on future product differentiators, product longevity & company-specific revenues/share per USA, EU, Developed ROW, and Emerging markets. It is ideally suited to organisations wishing to access an up-to-date, advanced global quantification of the RSV older adult, elderly monovalent and combination vaccines future market.
THIS PRODUCT IS A SUMMARY PRESENTATION (~375 slides, .pdf) + scenario-based interactive MS Excel Workbook(s)(~175 slides)
Photo credit: iStock (Getty Images)
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
